Molecular Partners AG (MOLN.SW)

CHF 3.2

(-1.24%)

Total Liabilities Summary of Molecular Partners AG

Molecular Partners AG's latest annual total liabilities in 2023 was 21.92 Million CHF , down -19.08% from previous year.
Molecular Partners AG's latest quarterly total liabilities in 2024 Q3 was 15.43 Million CHF , up 2.56% from previous quarter.
Molecular Partners AG reported annual total liabilities of 27.09 Million CHF in 2022, down -58.56% from previous year.
Molecular Partners AG reported annual total liabilities of 65.37 Million CHF in 2021, down -18.61% from previous year.
Molecular Partners AG reported quarterly total liabilities of 15.43 Million CHF for 2024 Q3, up 2.56% from previous quarter.
Molecular Partners AG reported quarterly total liabilities of 17.06 Million CHF for 2024 Q1, down -22.18% from previous quarter.

Annual Total Liabilities Chart of Molecular Partners AG (2023 - 2013)

Historical Annual Total Liabilities of Molecular Partners AG (2023 - 2013)

Year	Total Liabilities	Total Liabilities Growth
2023	21.92 Million CHF	-19.08%
2022	27.09 Million CHF	-58.56%
2021	65.37 Million CHF	-18.61%
2020	80.32 Million CHF	58.13%
2019	50.79 Million CHF	-19.95%
2018	63.45 Million CHF	129.12%
2017	27.69 Million CHF	-42.67%
2016	48.3 Million CHF	-28.55%
2015	67.6 Million CHF	48.44%
2014	45.53 Million CHF	-26.31%
2013	61.79 Million CHF	0.0%

Year	Total Liabilities	Total Liabilities Growth
2024 Q2	15.04 Million CHF	-11.79%
2024 Q3	15.43 Million CHF	2.56%
2024 Q1	17.06 Million CHF	-22.18%
2023 Q3	21.9 Million CHF	-10.63%
2023 FY	21.92 Million CHF	-19.08%
2023 Q1	22.37 Million CHF	-17.43%
2023 Q4	21.92 Million CHF	0.06%
2023 Q2	24.51 Million CHF	9.59%
2022 Q2	33.42 Million CHF	-29.41%
2022 Q4	27.09 Million CHF	-8.87%
2022 Q1	47.34 Million CHF	-27.58%
2022 Q3	29.73 Million CHF	-11.04%
2022 FY	27.09 Million CHF	-58.56%
2021 FY	65.37 Million CHF	-18.61%
2021 Q2	72.34 Million CHF	-7.57%
2021 Q4	65.37 Million CHF	25.88%
2021 Q3	51.93 Million CHF	-28.21%
2021 Q1	78.27 Million CHF	-2.55%
2020 Q2	42.32 Million CHF	0.0%
2020 Q4	80.32 Million CHF	0.0%
2020 Q1	- CHF	-100.0%
2020 FY	80.32 Million CHF	58.13%
2019 Q4	50.79 Million CHF	0.0%
2019 FY	50.79 Million CHF	-19.95%
2019 Q1	56.81 Million CHF	-10.46%
2019 Q2	56.81 Million CHF	0.0%
2019 Q3	50.79 Million CHF	-10.6%
2018 Q1	6.64 Million CHF	-75.99%
2018 Q2	11.09 Million CHF	66.91%
2018 Q4	63.45 Million CHF	72.12%
2018 Q3	36.86 Million CHF	232.24%
2018 FY	63.45 Million CHF	129.12%
2017 FY	27.69 Million CHF	-42.67%
2017 Q4	27.69 Million CHF	95.84%
2017 Q3	14.14 Million CHF	-66.93%
2017 Q2	42.76 Million CHF	0.0%
2017 Q1	- CHF	-100.0%
2016 FY	48.3 Million CHF	-28.55%
2016 Q3	- CHF	-100.0%
2016 Q1	- CHF	-100.0%
2016 Q4	48.3 Million CHF	0.0%
2016 Q2	59.18 Million CHF	0.0%
2015 Q4	67.6 Million CHF	0.0%
2015 Q2	50.53 Million CHF	0.0%
2015 Q1	- CHF	-100.0%
2015 FY	67.6 Million CHF	48.44%
2014 FY	45.53 Million CHF	-26.31%
2014 Q4	45.53 Million CHF	0.0%
2014 Q1	- CHF	0.0%
2013 FY	61.79 Million CHF	0.0%

Peer Total Liabilities Comparison of Molecular Partners AG

Name	Total Liabilities	Total Liabilities Difference
Addex Therapeutics Ltd	3.49 Million CHF	-527.013%
BB Biotech AG	304.9 Million CHF	92.81%
Basilea Pharmaceutica AG	183.29 Million CHF	88.039%
Evolva Holding SA	4.27 Million CHF	-412.747%
Idorsia Ltd	1.46 Billion CHF	98.507%
Kuros Biosciences AG	19.19 Million CHF	-14.218%
Relief Therapeutics Holding AG	24.16 Million CHF	9.267%
Santhera Pharmaceuticals Holding AG	49.68 Million CHF	55.877%